Human Papillomavirus |omicsgroup|Journal Of Biotechnology And Biomaterials

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Webinars & Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand

Human Papillomavirus

Human Papillomavirus (HPV) is the primary cause of cervical, anal, vulvar, vaginal and penile cancers as well as genital warts. To date, two prophylactic HPV vaccines are currently available in the Canadian market namely Gardasil and Cervarix. Gardasil, (approved in Canada July 2006) is Mercks quadrivalent HPV recombinant vaccine against HPV types 6, 11, 16 and 18. OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on August, 2021